Document is current
Any future updates will be listed below
-
Authors
Johal, Sukhvinder
Miranda, Miguel
Sarbajna, Tina
Shi, Xiaojin
Greystoke, Alastair
Johnson, Melissa
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03164616 at ClinicalTrials.govnct03164616 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
https://doi.org/10.1200/jco.22.00975
nct03215706 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
https://doi.org/10.1200/jco.22.00975
nct02578680 at ClinicalTrials.govDocuments that mention this clinical trial
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
https://doi.org/10.1200/jco.2024.42.16_suppl.8560
Tracking the tail
https://doi.org/10.1136/jitc-2020-000971
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
https://doi.org/10.1136/jitc-2023-008189
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9023
Documents that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
https://doi.org/10.1136/jitc-2021-sitc2021.364
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
https://doi.org/10.1200/jco.22.01989
